Evercore ISI Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by Evercore ISI from $220.00 to $260.00 in a report released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

ASND has been the subject of several other research reports. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 11th. Oppenheimer lowered their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a report on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $197.36.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $157.17 on Tuesday. The stock has a market capitalization of $9.54 billion, a P/E ratio of -19.45 and a beta of 0.64. The company has a 50 day moving average price of $133.20 and a 200 day moving average price of $132.57. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, research analysts forecast that Ascendis Pharma A/S will post -7.12 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently bought and sold shares of the business. Loomis Sayles & Co. L P raised its position in Ascendis Pharma A/S by 35.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after buying an additional 48,120 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after buying an additional 4,338 shares during the last quarter. Valence8 US LP purchased a new position in Ascendis Pharma A/S during the 3rd quarter worth $685,000. Nomura Asset Management Co. Ltd. raised its position in Ascendis Pharma A/S by 42.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after buying an additional 5,371 shares during the last quarter. Finally, Maven Securities LTD purchased a new position in Ascendis Pharma A/S during the 3rd quarter worth $7,466,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.